Merck & Co. Inc. (MRK)
Scotiabank increased its 12 month price target to $120 from $105, reflecting a stronger outlook for the company’s long-term growth trajectory. Analysts note that even as several of Merck’s mature products face mounting pressure from generic competition, the company continues to demonstrate solid operational execution, effective cost management, and consistent commercial performance across its key therapeutic areas. Merck’s diverse and innovation-driven product pipeline, supported by a number of late-stage candidates and potential label expansions positions the company well to generate new revenue streams that can more than compensate for losses from patent expirations. This combination of strategic resilience, sustained product momentum, and pipeline visibility underpins Scotiabank’s view that the stock warrants a higher valuation.
STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.
